Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. - Atreya, Raja; Ferrante, Marc; Panaccione, Remo; Feagan, Brian; Shchukina, Oksana; Jairath, Vipul; Rieder, Florian; Hisamatsu, Tadakazu; Siegmund, Britta; Kligys, Kristina; Song, Alexandra; Zambrano, Javier; et al. (Journal of Crohn's & Colitis, 2025)